title: Multidimensional pharmacologic strategies for diabetes.
abstract: Diabetes is a chronic disease associated with multisystem complications. In particular, cardiovascular and renal demise are almost certain in individuals who have diabetes, with cardiovascular complications account-ing for over 50% of mortality among patients who have type 2 diabetes mellitus. Documented benefits of lowering cholesterol, blood pressure, and glucose levels in these patients have led to the current emphasis on multidimensional pharmacologic management. Table 2 provides a summary of recommendations for managing patients who have type 2 diabetes.
authors.affiliation: School of Nursing, Middle Tennessee State University, Box 81, Murfreesboro, TN 37132, USA. edmisson@mtsu.edu
authors.forename: Ken W
authors.initials: KW
authors.lastname: Edmisson
mesh_terms: D000328:Adult; D000465:Algorithms; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015897:Comorbidity; D048909:Diabetes Complications / Q000453:epidemiology / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D003927:Diet, Diabetic; D015444:Exercise; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D015994:Incidence; D008019:Life Style; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011322:Primary Prevention / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001241:Aspirin; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors